Cystic fibrosis

Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series

Monday, October 25, 2021 - 12:00pm

Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform.

Key Points: 
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform.
  • MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis.
  • MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic amikacin, primarily used to treat chronic and acute bacterial infections.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Vertex to Announce Third-Quarter 2021 Financial Results on November 2

Friday, October 22, 2021 - 1:00pm

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close.
  • To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
  • Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

John King is recognized by Continental Who's Who

Thursday, October 21, 2021 - 10:24pm

ARGYLE, Texas, Oct. 21, 2021 /PRNewswire/ --John King is being recognized by Continental Who's Who as a Distinguished Executive for his excellent work in the Healthcare industry while at Vital Care Infusion and Kroger Specialty Pharmacies.

Key Points: 
  • ARGYLE, Texas, Oct. 21, 2021 /PRNewswire/ --John King is being recognized by Continental Who's Who as a Distinguished Executive for his excellent work in the Healthcare industry while at Vital Care Infusion and Kroger Specialty Pharmacies.
  • John King is currently serving as the Executive Vice President of Sales & Ops for Vital Care Infusion Services.
  • Mr. King was a member of the Marketing Association, Sigma Phi Epsilon, the Accounting Society, the Leadership Class, the Interfraternity Council, and Intramural Athletics.
  • Beginning in 2014, Mr. King served Regional Sales Director at TLCRx, which later was bought by the Kroger Co.

Lovelace Biomedical Presents a New Webinar on Rare Diseases and Gene Therapy Preclinical Research

Thursday, October 21, 2021 - 7:19pm

ALBUQUERQUE, N.M., Oct. 21, 2021 /PRNewswire/ --Lovelace Biomedical, a contract research organization, who has a vast and storied, 70 plus year history and expertise in studying respiratory diseases and developing therapeutics at the preclinical stage, will present a webinar in gene therapies for diseases, and will use Cystic Fibrosis results as a case study.

Key Points: 
  • ALBUQUERQUE, N.M., Oct. 21, 2021 /PRNewswire/ --Lovelace Biomedical, a contract research organization, who has a vast and storied, 70 plus year history and expertise in studying respiratory diseases and developing therapeutics at the preclinical stage, will present a webinar in gene therapies for diseases, and will use Cystic Fibrosis results as a case study.
  • Dr. McDonald will present on the framework for the use of rare disease models and regulatory considerations for safety.
  • Lovelace Biomedical is a contract research organization that conducts research to advance pharmaceutical and biotechnology companies in their complex drug development studies from the preclinical stage, and on to clinical trials.
  • For over 70 years, the organization has leveraged its multidisciplinary expertise in toxicology, gene therapy, neurological disorders, infectious disease, and medical countermeasures.

ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

Thursday, October 21, 2021 - 1:00pm

ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.

Key Points: 
  • ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the closing of an $80 million Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
  • Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, L.P., and Osage University Partners (OUP).
  • Oleg Nodelman, founder and portfolio manager of EcoR1 Capital also joined ReCodes Board of Directors in connection with the financing.
  • ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.

Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021

Thursday, October 21, 2021 - 1:00pm

CB-280 has the potential to be a first-in-class orally dosed arginase inhibitor that benefits all CF patients, regardless of CFTR genotype.

Key Points: 
  • CB-280 has the potential to be a first-in-class orally dosed arginase inhibitor that benefits all CF patients, regardless of CFTR genotype.
  • These statements include those related to Calitheras clinical trials in cystic fibrosis for the arginase inhibitor CB-280.
  • The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
  • In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release.

Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501

Thursday, October 21, 2021 - 12:00pm

MAT2501 is being developed to potentially become the first oral aminoglycoside, with the application of Matinas proprietary LNC platform technology to the broad-spectrum antibiotic drug amikacin.

Key Points: 
  • MAT2501 is being developed to potentially become the first oral aminoglycoside, with the application of Matinas proprietary LNC platform technology to the broad-spectrum antibiotic drug amikacin.
  • Our goal with MAT2501 is to develop the first oral aminoglycoside, which could transform the use of this important class of drugs, stated Jerome D. Jabbour, Chief Executive Officer of Matinas.
  • This Phase 1 study is a double-blind, placebo-controlled, SAD study designed primarily to evaluate the safety, tolerability and pharmacokinetics of single ascending oral doses of MAT2501 in healthy adult subjects.
  • MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic amikacin, primarily used to treat chronic and acute bacterial infections.

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thursday, October 21, 2021 - 1:00am

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $46.98 per share, the closing price of the Companys common stock as reported by Nasdaq on October 15, 2021.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

Tuesday, October 19, 2021 - 9:05pm

The data include more detailed results from the IND-enabling good laboratory practice (GLP) toxicology study of KB407 from which top line results were previously announced .

Key Points: 
  • The data include more detailed results from the IND-enabling good laboratory practice (GLP) toxicology study of KB407 from which top line results were previously announced .
  • Cystic fibrosis is the most common fatal inherited disease in the United States, affecting more than 80,000 patients worldwide.
  • Lack of functional CFTR in secretory airway epithelial cells causes dehydrated mucus buildup in the lungs, pancreas and other organs.
  • According to the US Cystic Fibrosis Foundation (CFF), the median age at death for patients with CF in the United States was 30.8 years in 2018.

First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis

Tuesday, October 19, 2021 - 2:24pm

The Phase 2a PASSPORT clinical trial is designed as a double-blind, placebo-controlled study to determine the safety, tolerability, and preliminary efficacy of FW-ICI-AC in the treatment of immune checkpoint inhibitor-associated colitis (ICI-AC) and diarrhea in advanced cancer patients.

Key Points: 
  • The Phase 2a PASSPORT clinical trial is designed as a double-blind, placebo-controlled study to determine the safety, tolerability, and preliminary efficacy of FW-ICI-AC in the treatment of immune checkpoint inhibitor-associated colitis (ICI-AC) and diarrhea in advanced cancer patients.
  • Additional endpoints will measure early signals of efficacy, including resolution of the patients diarrhea, sparing of steroids, and prevention of disease progression.
  • We are very pleased to have received IND clearance to initiate the PASSPORT clinical trial investigating FW-ICI-AC as a potential treatment for immune-checkpoint associated colitis and diarrhea.
  • FW-ICI-AC is a niclosamide-based, small molecule, anti-inflammatory inhibitor therapy for the treatment of immune checkpoint inhibitor-associated colitis (ICI-AC) and diarrhea in advanced cancer patients.